Quotes 5-day view Delayed Japan Exchange
06/29/2022
06/30/2022
07/01/2022
07/04/2022
07/05/2022
Date
2151.5(c)
2115(c)
2058.5(c)
2095.5(c)
2125
Last
8 173 000
7 866 700
6 149 000
3 378 900
3 480 700
Volume
-2.07%
-1.70%
-2.67%
+1.80%
+1.41%
Change
Estimated financial data (e) JPY USD
Sales 2022
1 320 B
9 728 M
9 728 M
Net income 2022
177 B
1 307 M
1 307 M
Net cash position 2022
340 B
2 507 M
2 507 M
P/E ratio 2022
22,3x
Yield 2022
2,39%
Sales 2023
1 434 B
10 568 M
10 568 M
Net income 2023
213 B
1 569 M
1 569 M
Net cash position 2023
350 B
2 579 M
2 579 M
P/E ratio 2023
17,9x
Yield 2023
2,86%
Capitalization
3 829 B
28 215 M
28 215 M
EV / Sales 2022
2,64x
EV / Sales 2023
2,43x
Nbr of Employees
14 522
Free-Float
98,9%
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Ratings of Astellas Pharma Inc.
All news about ASTELLAS PHARMA INC.
News in other languages on ASTELLAS PHARMA INC.
Chart ASTELLAS PHARMA INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ASTELLAS PHARMA INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
2 095,50 JPY
Average target price
2 546,15 JPY
Spread / Average Target
21,5%
Please enable JavaScript in your browser's settings to use dynamic charts.